ARTICLE | Company News
Zai Lab gets Chinese rights to Novocure's oncology tech
September 12, 2018 10:37 PM UTC
Novocure Ltd. (NASDAQ:NVCR) granted Zai Lab Ltd. (NASDAQ:ZLAB) exclusive rights to oncology platform Tumor Treating Fields in China, including Hong Kong and Macau, and Taiwan.
Novocure will receive $15 million up front and is eligible for $78 million in development, regulatory and commercial milestones, plus tiered royalties...